Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694037 | 0.89 | NPC1 (0.49) | MAPTRAB9ANPC1ATMALDH1A1 | |
| SCHEMBL6695432 | 0.78 | NPC1 (0.47) | MAPTRAB9ANPC1ATMALDH1A1 | |
| SCHEMBL6694823 | 0.78 | NPC1 (0.47) | MAPTRAB9ANPC1ATMALDH1A1 | |
| SCHEMBL6697320 | 0.78 | MAPT (0.40) | MAPTRAB9ANPC1ATMALDH1A1 | |
| SCHEMBL6697673 | 0.77 | MAPT (0.47) | MAPTRAB9ANPC1ATMALDH1A1 | |
| SCHEMBL6694814 | 0.76 | CYP1A2 (0.38) | MAPTATMALDH1A1KDM4EKMT2A | |
| SCHEMBL6701919 | 0.74 | MAPT (0.43) | MAPTATMALDH1A1L3MBTL1KDM4E | |
| SCHEMBL7044714 | 0.71 | MAPT (0.44) | MAPTRAB9ANPC1ALDH1A1L3MBTL1 | |
| SCHEMBL6701927 | 0.70 | MAPT (0.59) | MAPTRAB9ANPC1ATMALDH1A1 | |
| SCHEMBL7044716 | 0.70 | MAPT (0.42) | MAPTRAB9ANPC1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835726-B2 | Pyrimidine derivatives | AMGEN INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040006068-A1 | Pyrimidine derivatives | TULARIK INC. | 2004-01-08 | — | — | US | disclosed |
| EP-1056742-B1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6528513-B2 | Viricides; especially cytomegalo virus | TULARIK INC | 2003-03-04 | — | — | US | disclosed |
| US-20010018436-A1 | Pyrimidine derivatives | TULARIK INC. | 2001-08-30 | — | — | US | disclosed |
| US-6200977-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1056742-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999041253-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018436-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | MAPT 1762/4885RAB9A 3813/4885NPC1 2412/4885 |
| US-20040006068-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | MAPT 1762/4885RAB9A 3813/4885NPC1 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.